Alerts will be sent to your verified email
Verify EmailLINCOLN
|
Lincoln Pharma
|
Ind-Swift Lab.
|
Wanbury
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
|
R&D as a % of Total Sales
|
1.88 % | 2.9 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
15.1 % | 14.53 % | -11.27 % |
|
5yr average Equity Multiplier
|
1.26 | 2.17 | -1.35 |
|
5yr Average Asset Turnover Ratio
|
0.82 | 0.66 | 1.54 |
|
5yr Avg Net Profit Margin
|
14.59 % | 16.17 % | 5.09 % |
|
Price to Book
|
1.3 | 0.68 | 12.72 |
|
P/E
|
11.66 | 3.56 | 17.55 |
|
5yr Avg Cash Conversion Cycle
|
-6.41 Days | 15.71 Days | -103.0 Days |
|
Inventory Days
|
43.91 Days | 103.91 Days | 21.96 Days |
|
Days Receivable
|
91.75 Days | 105.66 Days | 61.39 Days |
|
Days Payable
|
128.38 Days | 107.02 Days | 194.51 Days |
|
5yr Average Interest Coverage Ratio
|
63.13 | 21.19 | 2.13 |
|
5yr Avg ROCE
|
19.81 % | 12.09 % | -37.9 % |
|
5yr Avg Operating Profit Margin
|
18.35 % | 14.94 % | 7.72 % |
|
5 yr average Debt to Equity
|
0.0 | 0.91 | 0.2 |
|
5yr CAGR Net Profit
|
5.76 % | n/a | n/a |
|
5yr Average Return on Assets
|
11.92 % | 11.49 % | 7.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.78 % | 39.5 % | 43.07 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 62.18 % |
|
Change in Promoter Holding (3 Yrs)
|
3.44 % | -2.5 % | 3.23 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Lincoln Pharma
|
Ind-Swift Lab.
|
Wanbury
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|